REVIEW
|
doi:10.20944/preprints202305.0122.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Non-small cell lung cancer (NSCLC); EGFR; Tyrosine kinase inhibitors (TKIs); Uncommon mutation; Compound mutation; Intracranial activity; Immunotherapy
Online: 3 May 2023 (09:29:08 CEST)